Pharmaceuticals

Everest Medicines Announces Inclusion of VELSIPITY® and XERAVA® in China's 2026 National Reimbursement Drug List

SHANGHAI, Nov. 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that VELSIPITY® (etrasimod arginine t...

2026-11-16 19:48 898

Ampang Puteri Specialist Hospital Launches KPJ Healthcare's First Dedicated International Patient Ward

33-bed facility enhances healthcare tourism services with dedicated inpatient accommodation, multilingual assistance and personalised patient support KUALA LUMPUR, Malaysia, Nov. 16, 2026 /PRNewswire/ -- Ampang Puteri Specialist Hospital ("APSH"), part of the KPJ Healthcare Berhad ("KPJ Healthca...

2026-11-16 18:23 1023

Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026

- ASC30_48 FDC, a first-in-class once-daily oral dual fixed-dose combination targeting GLP-1R and GIPR, achieved approximately 52% relative improvement in weight loss compared to ASC30 alone - ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist designed for once-monthly to once-quarterly subcutaneo...

2026-11-16 17:10 1589

Orphalan Expands Global Phase 3 TRADITiONAL Study in Wilson Disease to China Marking First Patient Randomised Worldwide

* Phase 3 trial evaluates the safety and efficacy of an investigational once-daily formulation of trientine tetrahydrochloride compared to D-penicillamine as first-line treatment in Wilson disease. * First participant globally randomised in China at The Second Affiliated Hospital of Zhejiang...

2026-11-16 09:00 1104

AJOVY® Formally Included in China's National Reimbursement Drug List 2026

SHANGHAI, Nov. 14, 2026 /PRNewswire/ -- On November 14, NeuroGen announced that it's in-licensed innovative drugAJOVY® (fremanezumab injection) from TEVA has been successfully listed on China's National Reimbursement Drug List (NRDL) following the latest round of national price negotiations1. Mar...

2026-11-14 21:51 2130

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

SHANGHAI and CAMBRIDGE, Mass, Nov. 14, 2026 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National...

2026-11-14 13:38 5893

GHA Honors The Second Affiliated Hospital Zhejiang University School of Medicine with Distinction for Excellence in International Medical Travel Patient Experience

PALM BEACH GARDENS, Fla., Nov. 14, 2026 /PRNewswire/ -- GHA is pleased to announce that The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), located in Hangzhou, China, has received the GHA Certification of Excellence in International Medical Travel Patient Experience w...

2026-11-14 04:00 4681

HTL Biotechnology launches HTL8, a production unit dedicated to pharmaceutical-grade polynucleotides (DNA)

JAVENÉ, France, Nov. 13, 2026 /PRNewswire/ -- Thursday, November 12, HTL Biotechnology, a world leader in the development and production of pharmaceutical-grade biopolymers, inaugurated its new production unit, HTL8, dedicated to the manufacture of pharmaceutical-grade polynucleotides, at its Ja...

2026-11-13 16:30 1192

Nine Listings Transfer to the NYSE in 2026 Amounting to $500B in Market Cap

Large-cap transfers and a broad issuer community point to the strength of the NYSE. In addition NYSE's state of the art technology processed a new peak in message volumes on November 5. Key takeaways * The transfers: Nine companies have moved from Nasdaq to the NYSE year to date, including th...

2026-11-13 02:09 3698

Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Nov. 12, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune d...

2026-11-12 11:21 749

Vitamin Angels Partners with Government of Cambodia to Advance Scale-Up of MMS and Reach One-Third of Pregnant Women in 2027

* Approximately 51% of pregnant women in Cambodia experience anemia . Maternal anemia increases the risk...

2026-11-12 02:02 682

Shanton Pharma Receives EMA and FDA Pediatric Study Waivers for SAP-001 in Hyperuricemia

Pediatric clinical studies of SAP-001 in hyperuricemia and gout are not needed Significant clinical trial burden and costs avoided due to waiver SINGAPORE and PRINCETON, N.J., Nov. 11, 2026 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech developing a novel treatment for hyperuricemia an...

2026-11-11 21:00 469

Immunofoco Presents a Novel In Vivo TCE Delivery Strategy Using Lentiviral Vectors at SITC 2026

SHANGHAI, Nov. 11, 2026 /PRNewswire/ -- At the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2026), held November 4–8 in Phoenix, Arizona, Immunofoco, in collaboration with Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Shanghai East Hospital, Tongji ...

2026-11-11 20:57 385

Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity

-  ASC30_39 FDC, a once-daily oral fixed-dose combination (FDC) tablet of small molecule GLP-1R agonist ASC30 and small molecule selective amylin receptor agonist ASC39, is the first co-formulation of an oral GLP-1 and an oral amylin to reach Investigational New Drug submission. -  ASC30_39 FDC ...

2026-11-11 17:10 690

Telix to Participate in UBS Global Biopharma Conference

MELBOURNE, Australia and INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") will participate in the upcoming UBS Global Biopharma Conference in London (UK). Dr. Christian Behrenbruch, Managing Director and Group CEO, and Mr. Richard Valeix,...

2026-11-11 15:00 522

Beyond Medical Group and Tamarind Health Advance Regional Expansion Through Strategic Partnership in Cambodia

Alliance with SingMed International Medical Centre strengthens Singapore–Cambodia healthcare cooperation and establishes a platform for cross-border specialist and oncology services. PHNOM PENH, Cambodia, Nov. 11, 2026 /PRNewswire/ -- 10 November 2026, Beyond Medical Group (BMG) and Tamarind Hea...

2026-11-11 12:54 986

Daewoong Pharmaceutical Hosts Exclusive Global KOL Summit in Bali to Shape the Future of NABOTA

- 21 leading KOLs from 11 countries selected to attend NMC EXCLUSIVE, an invitation-only advanced educational program that builds on the existing NABOTA Master Class - In-depth lectures and roundtable discussions facilitate the exchange of advanced clinical expertise and explore common approache...

2026-11-11 11:02 1135

Lundbeck raises full-year guidance as 9M revenue grows +13% CER (+11% CER underlying) and adjusted EBITDA +19% CER, led by Vyepti®

VALBY, Denmark, Nov. 10, 2026 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +13% CER[1] (+9% DKK) to DKK 20,191 million in the first nine months of 2026, with all regions contributing to the growth. The performance reflected strong Vyepti® growth, supported by solid contributi...

2026-11-10 20:14 1952

Lundbeck raises financial guidance for 2026

VALBY, Denmark, Nov. 10, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) raises its full-year 2026 guidance for revenue and adjusted EBITDA growth at constant exchange rates (CER). Lundbeck has increased its 2026 revenue outlook, primarily reflecting the continued strong performance of Vyepti® i...

2026-11-10 20:12 1525

World First! LivingPHOENIX Secures China's First Medical Device Registration Certificate for Biomimetic Collagen, Ushering in the Era of Third-Generation "Biomimetic Collagen ECM"

CHENGDU, China, Nov. 10, 2026 /PRNewswire/ -- On November 6, at the 2026 Golden Panda Global Innovation and Entrepreneurship Competition, LivingPHOENIX Regenerative Technology Development (Chengdu) Co., Ltd. ("LivingPHOENIX") achieved a historic milestone: its independently developed "Sterile Bio...

2026-11-10 09:49 3086
12345 ... 185